Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep;17(4-5):693-706.
doi: 10.1007/s10741-011-9266-y.

Tissue inhibitor of metalloproteinases (TIMPs) in heart failure

Linn Moore  1 , Dong Fan, Ratnadeep Basu, Vijay Kandalam, Zamaneh Kassiri
Affiliations
Review

Tissue inhibitor of metalloproteinases (TIMPs) in heart failure

Linn Moore et al. Heart Fail Rev. 2012 Sep.

Abstract

Remodeling of the myocardium and the extracellular matrix (ECM) occurs in heart failure irrespective of its initial cause. The ECM serves as a scaffold to provide structural support as well as housing a number of cytokines and growth factors. Hence, disruption of the ECM will result in structural instability as well as activation of a number of signaling pathways that could lead to fibrosis, hypertrophy, and apoptosis. The ECM is a dynamic entity that undergoes constant turnover, and the integrity of its network structure is maintained by a balance in the function of matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitor of metalloproteinases (TIMPs). In heart disease, levels of MMPs and TIMPs are altered resulting in an imbalance between these two families of proteins. In this review, we will discuss the structure, function, and regulation of TIMPs, their MMP-independent functions, and their role in heart failure. We will review the knowledge that we have gained from clinical studies and animal models on the contribution of TIMPs in the development and progression of heart disease. We will further discuss how ECM molecules and regulatory genes can be used as biomarkers of disease in heart failure patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Crit Rev Clin Lab Sci. 2004;41(3):233-64 - PubMed
    1. Int J Cardiol. 2011 Aug 4;150(3):277-82 - PubMed
    1. Int J Cardiol. 2008 Nov 12;130(2):147-58 - PubMed
    1. Biochem Biophys Res Commun. 2000 Nov 30;278(3):511-5 - PubMed
    1. Int J Biochem Cell Biol. 2008;40(6-7):1362-78 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources